Inovio Pharmaceuticals Inc  

(Public, NASDAQ:INO)   Watch this stock  
Find more results for AMEX:INO
7.05
-0.12 (-1.67%)
Mar 3 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.95 - 7.24
52 week 6.33 - 15.56
Open 7.18
Vol / Avg. 0.00/646,922.00
Mkt cap 434.75M
P/E     -
Div/yield     -
EPS -0.79
Shares 60.59M
Beta 2.72
Inst. own 29%
Feb 9, 2015
Inovio Pharmaceuticals Inc at Biotechnology Industry Organization CEO & Investor Conference
Feb 5, 2015
Inovio Pharmaceuticals Inc at Emerald Research Groundhog Day Investment Forum
Jan 12, 2015
Inovio Pharmaceuticals Inc at EBD Biotech Showcase
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -390.09% -490.69%
Operating margin -452.69% -145.12%
EBITD margin - -139.17%
Return on average assets -20.81% -99.06%
Return on average equity -24.13% -152.12%
Employees 71 -
CDP Score - -

Address

10480 WATERIDGE CIRCLE
SAN DIEGO, CA 92121
United States - Map
+1-858-5976006 (Phone)
+1-267-4404242 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Inovio Pharmaceuticals, Inc. is engaged in the development of a new generation of vaccines, called synthetic vaccines, focused on cancers and infectious diseases. The Company's SynCon technology enables the design of universal vaccines capable of providing cross-protection against existing or changing strains of pathogens, such as influenza and human immunodeficiency virus (HIV). The Company's electroporation delivery technology uses brief, controlled electrical pulses to increase cellular uptake of the vaccine. The Company's clinical programs include cervical dysplasia (therapeutic), avian influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus (HCV) and HIV vaccines. It is advancing preclinical research and clinical development for a universal seasonal/pandemic influenza vaccine, as well as preclinical work for other products, including malaria and prostate cancer vaccines. As of December 31, 2011 it owned 16.1% interest in VGX Int�l.

Officers and directors

J. Joseph Kim Ph.D. President, Chief Executive Officer, Director
Age: 45
Bio & Compensation  - Reuters
Peter D. Kies Chief Financial Officer
Age: 50
Bio & Compensation  - Reuters
Niranjan Y. Sardesai Ph.D. Chief Operating Officer
Age: 46
Bio & Compensation  - Reuters
Jennifer Laux Vice President - Commercial
Bio & Compensation  - Reuters
Zane Yang Vice President - Clinical Development, Oncology
Bio & Compensation  - Reuters
Mark L. Bagarazzi M.D. Chief Medical Officer
Age: 53
Bio & Compensation  - Reuters
Avtar S. Dhillon M.D. Non-Executive Chairman of the Board
Age: 52
Bio & Compensation  - Reuters
Simon X. Benito Independent Director
Age: 69
Bio & Compensation  - Reuters
Angel Cabrera Ph.D. Independent Director
Age: 46
Bio & Compensation  - Reuters
Mort Collins Ph.D. Independent Director
Age: 78
Bio & Compensation  - Reuters